Xeris Biopharma Holdings, Inc. (XERS)

$1.54

-0.02 (-1.28%)
Rating:
Recommendation:
-
Symbol XERS
Price $1.54
Beta 1.810
Volume Avg. 0.82M
Market Cap 209.374M
Shares () -
52 Week Range 1.25-3.17
1y Target Est -
DCF Unlevered XERS DCF ->
DCF Levered XERS LDCF ->
ROE -207.77% Strong Sell
ROA -42.90% Strong Sell
Operating Margin -
Debt / Equity 330.89% Strong Buy
P/E -
P/B 2.82 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest XERS news


Mr. Paul Edick
Healthcare
Biotechnology
NASDAQ Global Select

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.